196 related articles for article (PubMed ID: 28972294)
1. Cancer/testis antigen SPATA19 is frequently expressed in benign prostatic hyperplasia and prostate cancer.
Wong KK; Hussain FA; Loo SK; López JI
APMIS; 2017 Dec; 125(12):1092-1101. PubMed ID: 28972294
[TBL] [Abstract][Full Text] [Related]
2. The prostate cancer immunome: In silico functional analysis of antigenic proteins from microarray profiling with IgG.
Luna-Coronell JA; Vierlinger K; Gamperl M; Hofbauer J; Berger I; Weinhäusel A
Proteomics; 2016 Apr; 16(8):1204-14. PubMed ID: 27089054
[TBL] [Abstract][Full Text] [Related]
3. Elevated expression levels of testis-specific genes TEX101 and SPATA19 in basal cell carcinoma and their correlation with clinical and pathological features.
Ghafouri-Fard S; Abbasi A; Moslehi H; Faramarzi N; Taba Taba Vakili S; Mobasheri MB; Modarressi MH
Br J Dermatol; 2010 Apr; 162(4):772-9. PubMed ID: 19886887
[TBL] [Abstract][Full Text] [Related]
4. Novel potential serological prostate cancer biomarkers using CT100+ cancer antigen microarray platform in a multi-cultural South African cohort.
Adeola HA; Smith M; Kaestner L; Blackburn JM; Zerbini LF
Oncotarget; 2016 Mar; 7(12):13945-64. PubMed ID: 26885621
[TBL] [Abstract][Full Text] [Related]
5. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
[TBL] [Abstract][Full Text] [Related]
6. Expression of two testis-specific genes, SPATA19 and LEMD1, in prostate cancer.
Ghafouri-Fard S; Ousati Ashtiani Z; Sabah Golian B; Hasheminasab SM; Modarressi MH
Arch Med Res; 2010 Apr; 41(3):195-200. PubMed ID: 20682177
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer antigen-1 as a potential novel marker for prostate cancer.
Liu BQ; Wu YD; Li PH; Wei JX; Zhang T; Liu RL
Asian J Androl; 2007 Nov; 9(6):821-6. PubMed ID: 17968469
[TBL] [Abstract][Full Text] [Related]
8. Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer.
Li J; Dai L; Lei N; Xing M; Li P; Luo C; Casiano CA; Zhang JY
Oncotarget; 2016 Jul; 7(28):43546-43556. PubMed ID: 27286458
[TBL] [Abstract][Full Text] [Related]
9. Klf4 transcription factor is expressed in the cytoplasm of prostate cancer cells.
Le Magnen C; Bubendorf L; Ruiz C; Zlobec I; Bachmann A; Heberer M; Spagnoli GC; Wyler S; Mengus C
Eur J Cancer; 2013 Mar; 49(4):955-63. PubMed ID: 23089465
[TBL] [Abstract][Full Text] [Related]
10. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
[TBL] [Abstract][Full Text] [Related]
11. [Tumor infiltrating dendritic cells and Mucin1 gene expression in benign prostatic hyperplasia and prostate cancer].
Xiang ST; Zhou SW; Guan W; Wang QZ; Zhang B; Liu JH; Ye ZQ
Zhonghua Nan Ke Xue; 2003 Oct; 9(7):497-500. PubMed ID: 14628595
[TBL] [Abstract][Full Text] [Related]
12. Overexpressed Rce1 is positively correlated with tumor progression and predicts poor prognosis in prostate cancer.
Huang L; Li M; Wang D; He J; Wu W; Zeng Q; Li J; Xiao M; Hu J; He Y; Li Y; Mai L; Liu W
Hum Pathol; 2016 Jan; 47(1):109-14. PubMed ID: 26546252
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NY-ESO-1 in cancerous and benign prostatic tissue.
Hudolin T; Juretic A; Spagnoli GC; Pasini J; Bandic D; Heberer M; Kosicek M; Cacic M
Prostate; 2006 Jan; 66(1):13-8. PubMed ID: 16114059
[TBL] [Abstract][Full Text] [Related]
14. Tissue concentrations of prostate-specific antigen in prostatic carcinoma and benign prostatic hyperplasia.
Pretlow TG; Pretlow TP; Yang B; Kaetzel CS; Delmoro CM; Kamis SM; Bodner DR; Kursh E; Resnick MI; Bradley EL
Int J Cancer; 1991 Nov; 49(5):645-9. PubMed ID: 1718912
[TBL] [Abstract][Full Text] [Related]
15. STEAP1 protein overexpression is an independent marker for biochemical recurrence in prostate carcinoma.
Ihlaseh-Catalano SM; Drigo SA; de Jesus CM; Domingues MA; Trindade Filho JC; de Camargo JL; Rogatto SR
Histopathology; 2013 Nov; 63(5):678-85. PubMed ID: 24025158
[TBL] [Abstract][Full Text] [Related]
16. [Expressions of endothelin-1 in benign prostatic hyperplasia and prostate cancer and their significance].
Zhou WQ; Sun YH; Yin HL; Zhang ZY; Ge JP; Cheng W; Ma HQ; Wei W; Zhou SG; Ma HH; Gao JP
Zhonghua Nan Ke Xue; 2007 Aug; 13(8):685-9. PubMed ID: 17918704
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression of topoisomerase II alpha and Her-2/neu in prostatic carcinoma and benign prostatic hyperplasia.
Hasby EA; Saied EM
J Egypt Natl Canc Inst; 2008 Jun; 20(2):158-67. PubMed ID: 20029472
[TBL] [Abstract][Full Text] [Related]
18. Expression of neutral amino acid transporter ASCT2 in human prostate.
Li R; Younes M; Frolov A; Wheeler TM; Scardino P; Ohori M; Ayala G
Anticancer Res; 2003; 23(4):3413-8. PubMed ID: 12926082
[TBL] [Abstract][Full Text] [Related]
19. Progression of benign prostatic hyperplasia is associated with pro-inflammatory mediators and chronic activation of prostate-infiltrating lymphocytes.
Norström MM; Rådestad E; Sundberg B; Mattsson J; Henningsohn L; Levitsky V; Uhlin M
Oncotarget; 2016 Apr; 7(17):23581-93. PubMed ID: 26993768
[TBL] [Abstract][Full Text] [Related]
20. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]